447 related articles for article (PubMed ID: 25277394)
1. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
Koehler JA; Baggio LL; Cao X; Abdulla T; Campbell JE; Secher T; Jelsing J; Larsen B; Drucker DJ
Diabetes; 2015 Mar; 64(3):1046-56. PubMed ID: 25277394
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice.
Koehler JA; Baggio LL; Lamont BJ; Ali S; Drucker DJ
Diabetes; 2009 Sep; 58(9):2148-61. PubMed ID: 19509017
[TBL] [Abstract][Full Text] [Related]
3. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
Nakamura T; Ito T; Uchida M; Hijioka M; Igarashi H; Oono T; Kato M; Nakamura K; Suzuki K; Jensen RT; Takayanagi R
Lab Invest; 2014 Jan; 94(1):63-78. PubMed ID: 24217090
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
McKay NJ; Kanoski SE; Hayes MR; Daniels D
Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
[TBL] [Abstract][Full Text] [Related]
5. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Pyke C; Heller RS; Kirk RK; Ørskov C; Reedtz-Runge S; Kaastrup P; Hvelplund A; Bardram L; Calatayud D; Knudsen LB
Endocrinology; 2014 Apr; 155(4):1280-90. PubMed ID: 24467746
[TBL] [Abstract][Full Text] [Related]
7. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
8. Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats.
Sisley S; Smith K; Sandoval DA; Seeley RJ
Peptides; 2014 Aug; 58():1-6. PubMed ID: 24879927
[TBL] [Abstract][Full Text] [Related]
9. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
[TBL] [Abstract][Full Text] [Related]
10. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.
Romaní-Pérez M; Outeiriño-Iglesias V; Gil-Lozano M; González-Matías LC; Mallo F; Vigo E
Endocrinology; 2013 Mar; 154(3):1144-55. PubMed ID: 23354098
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
13. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
14. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
[TBL] [Abstract][Full Text] [Related]
16. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?
Gale EA
Diabetes; 2012 May; 61(5):986-8. PubMed ID: 22517653
[No Abstract] [Full Text] [Related]
17. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Kim M; Platt MJ; Shibasaki T; Quaggin SE; Backx PH; Seino S; Simpson JA; Drucker DJ
Nat Med; 2013 May; 19(5):567-75. PubMed ID: 23542788
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.
Hou Y; Ernst SA; Heidenreich K; Williams JA
Am J Physiol Gastrointest Liver Physiol; 2016 Jan; 310(1):G26-33. PubMed ID: 26542397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
